新普京(中国·澳门)娱乐场官方网站-PC platform

2024-04-29

Good news! NKF and Livzon export Cetrorelix Acetate for Injection first time to US

Return

On April 27, 2024, Nanjing King-Friend Biochemical Pharmaceutical Co.Ltd (hereinafter referred to as "NKF") and Livzon Group export Cetrorelix Acetate for Injection to the United States for the first time.



Cetrorelix Acetate for Injection is the first product NKF introduced from China, reflecting the high recognition of NKF’s overseas platform from domestic partners. At the same time, it only takes less than one week from getting approval notification to the first shipment, which shows the "NKF speed" once again.



Striving for more than 30 years, NKF upholds the pure and devout spirit of pharmaceutical manufacturers, always working with the mission and responsibility of “driving the development of domestic pharmaceutical industry with international recognized drug quality, entering the international pharmaceutical market by virtue of international recognized ability, and striving for the health and well-being of society and humanity". NKF is constantly committed to promoting Chinese injection products to go abroad and expand into the international market.


In recent years, NKF has continuously expanded cooperation with international pharmaceutical giants such as Pfizer, Sanofi, and Novartis in API business. The company's listed FDF products include anticoagulants, cardiovascular, oncology, anesthetics, and surgical adjuvant drugs. The facility is approved by the US FDA, EU EDQM, Japan PMDA, Brazil ANVISA, and the UK MHRA, and products mainly sold to the United States, Europe, Brazil, the UK, Japan, and other places.


The Cetrorelix Acetate for injection will be scheduled to launch in the United States in the near future, benefiting more patients. NKF will continue the path of innovation-driven development, enhance its core competitiveness, and utilize its mature and perfect foreign marketing platform, in order to serve domestic partners, broaden circle of friends and expand international influence.


Adhering to the concept of "excellent operation and shared development", NKF will continue to deepen its expertise in the pharmaceutical field, creating high-quality drugs with ingenuity, allowing good drugs to smoothly step out the laboratory and enter global market, and striving to enable more global patients to enjoy the life benefits brought by drug innovation together, safeguarding human health.